Published in PLoS One on June 19, 2009
Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. PLoS One (2015) 1.39
Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One (2011) 1.14
Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol J (2010) 1.02
Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J Virol (2009) 1.01
Innate immune evasion strategies of influenza viruses. Future Microbiol (2010) 1.00
Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clin Vaccine Immunol (2011) 0.99
NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge. J Virol (2012) 0.95
Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One (2012) 0.89
Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int (2015) 0.89
Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine. Cell Mol Immunol (2010) 0.88
Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J Gen Virol (2010) 0.88
Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. J Virol (2011) 0.83
Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza. Viruses (2012) 0.82
Mutations in the M-gene segment can substantially increase replication efficiency of NS1 deletion influenza A virus in MDCK cells. J Virol (2012) 0.82
The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014. Antiviral Res (2015) 0.82
Principles underlying rational design of live attenuated influenza vaccines. Clin Exp Vaccine Res (2012) 0.78
Avian influenza virus NS1: A small protein with diverse and versatile functions. Virulence (2013) 0.78
Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J (2014) 0.77
A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A (2000) 12.16
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med (2006) 9.73
Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med (2007) 6.54
Type 1 interferons and the virus-host relationship: a lesson in détente . Science (2006) 6.33
Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity (1998) 5.98
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet (2006) 5.72
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest (1998) 5.70
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet (2006) 4.22
Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev (2006) 4.13
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med (2004) 4.10
MDA5/RIG-I and virus recognition. Curr Opin Immunol (2008) 4.05
Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol (1994) 3.86
Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology (2003) 3.77
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med (2006) 3.71
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med (2008) 3.28
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev (2008) 2.69
Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol (1984) 2.57
Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol (1998) 2.42
Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin Microbiol Rev (2008) 2.39
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One (2008) 2.18
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A (2005) 2.13
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine (2003) 2.04
Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J (2006) 1.98
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog (2008) 1.83
Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. Infect Immun (2002) 1.79
Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis (2005) 1.79
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 1.78
Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol (2007) 1.78
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol (2006) 1.69
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine (2008) 1.52
Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine (2003) 1.49
Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis (2006) 1.48
Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand (1979) 1.45
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine (2005) 1.42
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine (2008) 1.40
Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol (1992) 1.40
Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol (1992) 1.38
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine (2007) 1.35
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine (2008) 1.35
Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics (2006) 1.34
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis (1977) 1.26
Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol (2004) 1.23
The influenza virus NS1 protein: inhibitor of innate and adaptive immunity. Infect Disord Drug Targets (2007) 1.21
Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine (2008) 1.20
Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine (2006) 1.16
A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J (2006) 1.09
Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature. Clin Drug Investig (1998) 1.02
Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol (2005) 1.02
Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice. J Gen Virol (2004) 0.99
Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine (2007) 0.95
Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine (1991) 0.93
Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis (1997) 0.89
Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine (2004) 0.88
A novel, quantitative bioassay for type I interferon using a recombinant indicator cell line. Biotechnology (N Y) (1990) 0.83
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 4.74
Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 2.62
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci (2002) 2.32
Enantioselective Construction of Quaternary Stereocenters. Angew Chem Int Ed Engl (2001) 2.08
Potential role of human challenge studies for investigation of influenza transmission. Lancet Infect Dis (2011) 1.98
Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke (2002) 1.88
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis (2012) 1.82
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology (2003) 1.70
The burden of influenza B: a structured literature review. Am J Public Health (2013) 1.69
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
Animal models in influenza vaccine testing. Expert Rev Vaccines (2008) 1.60
Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release (2003) 1.54
Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology (2004) 1.45
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine (2009) 1.37
Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis (2001) 1.22
Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. J Infect Dis (2011) 1.20
Mesh graft infection following abdominal hernia repair: risk factor evaluation and strategies of mesh graft preservation. A retrospective analysis of 476 operations. World J Surg (2010) 1.20
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis (2010) 1.18
Meeting report: risk assessment of tamiflu use under pandemic conditions. Environ Health Perspect (2008) 1.15
Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One (2011) 1.14
Transformation of the cyanobacterium Synechocystis sp. PCC 6803 as a tool for genetic mapping: optimization of efficiency. FEMS Microbiol Lett (2002) 1.14
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med (2013) 1.03
Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Biotechnol J (2010) 1.02
Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol (2005) 1.02
Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res (2004) 1.01
Nitrate and the GATA factor AreA are necessary for in vivo binding of NirA, the pathway-specific transcriptional activator of Aspergillus nidulans. Mol Microbiol (2002) 1.01
Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J Biol Chem (2004) 0.99
Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int J Cancer (2004) 0.98
TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg (2002) 0.98
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV. Antivir Chem Chemother (2005) 0.97
Pre-clinical safety evaluation of pyrrolidine dithiocarbamate. Basic Clin Pharmacol Toxicol (2010) 0.96
Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol (2006) 0.95
Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model. J Infect Dis (2014) 0.95
Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology (2003) 0.95
Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. AIDS (2002) 0.93
Human microbial challenge: the ultimate animal model. Lancet Infect Dis (2012) 0.93
Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice. J Gen Virol (2009) 0.93
Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses. Cancer Res (2006) 0.92
Recurrent abscess after primary successful endo-sponge treatment of anastomotic leakage following rectal surgery. World J Gastroenterol (2010) 0.92
Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine (2011) 0.90
Identification of HLA-A*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2. J Immunol (2002) 0.90
Autophagy is induced by UVA and promotes removal of oxidized phospholipids and protein aggregates in epidermal keratinocytes. J Invest Dermatol (2013) 0.90
Expression of human endogenous retrovirus K is stimulated by ultraviolet radiation in melanoma. Pigment Cell Melanoma Res (2011) 0.89
Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One (2012) 0.89
Epidermal keratinocytes form a functional skin barrier in the absence of Atg7 dependent autophagy. J Dermatol Sci (2013) 0.89
Immunoglobulin G specifically binding plant N-glycans with high affinity could be generated in rabbits but not in mice. Glycobiology (2005) 0.88
Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS One (2012) 0.88
Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget (2013) 0.87
Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS One (2012) 0.87
Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture. Cancer Immunol Immunother (2007) 0.87
Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Respir Res (2007) 0.87
Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. Int J Mol Sci (2012) 0.87
Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. Med Microbiol Immunol (2009) 0.86
Influenza a virus induces an immediate cytotoxic activity in all major subsets of peripheral blood mononuclear cells. PLoS One (2009) 0.86
GMP production of liposomes--a new industrial approach. J Liposome Res (2006) 0.86
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest (2013) 0.86
Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency. J Virol (2010) 0.85
Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep (2009) 0.85